AstraZeneca has made a significant decision regarding its drug Zoladex, which is used for treating breast cancer and endometriosis. The pharmaceutical company has stated that it will offer the medication to patients without charge indefinitely. This move comes as a response to concerns from breast cancer patients who were contemplating the removal of their ovaries due to the drug’s accessibility issues.
Previously, there were discussions around listing Zoladex on the Pharmaceutical Benefits Scheme (PBS) in Australia. However, AstraZeneca has opted to provide the medication for free instead of going through the PBS listing process. This decision is expected to alleviate the financial burden on patients who rely on this medication as part of their treatment.
The announcement has been welcomed by many in the medical community, as it ensures that patients will have uninterrupted access to this crucial drug. The availability of Zoladex is vital for those managing symptoms of endometriosis as well as for breast cancer patients undergoing hormone therapy.
This initiative by AstraZeneca highlights the company’s commitment to patient care and support, particularly for those facing serious health challenges. The decision is seen as a proactive approach to ensuring that patients have the necessary resources to manage their conditions effectively.
For further details, you can refer to ABC News, which reported on this development on July 30, 2026.
Source: ABC News & Headlines – Australian Broadcasting Corporation